autologous adult pancreatic progenitor-derived islets

Autologous adult pancreatic progenitor-derived islets (AIP cells) is an investigational cell therapy being developed for the treatment of insulin-dependent diabetes, specifically Type 1 Diabetes Mellitus. Developed primarily by **Orgenesis**, the therapy utilizes a proprietary trans-differentiation process to convert a patient's own adult progenitor cells—typically harvested from liver tissue due to its shared developmental origin with the pancreas—into functional, glucose-responsive, insulin-secreting islet-like clusters. This autologous approach aims to restore endogenous insulin production and glycemic control while eliminating the risk of transplant rejection and the subsequent need for lifelong immunosuppression. The cells are typically re-implanted into the patient via intraportal infusion or through a specialized vascularized scaffold, effectively replacing the function of destroyed beta cells.

Other names

autologous insulin-producing cellsAIP cellstrans-differentiated autologous insulin-producing cellsautologous adult pancreatic progenitor cells